Atai Life Sciences N.V. (ATAI)

$4.48 -0.80 (-15.15%)
Market Cap 1.25B
Revenue (ttm) 310,000.00
Net Income (ttm) -149.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -48,151.61%
Debt to Equity Ratio 0.00
Volume 10,284,041
Avg Vol 5,985,524
Day's Range N/A - N/A
Shares Out 233.78M
Stochastic %K 10%
Beta 1.59
Analysts Strong Sell
Price Target $12.12

Company Profile

Atai Beckley N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 793 2536
Address:
Prof. J.H. Bavincklaan 7, Amstelveen, Netherlands
LibertarianTreehugger
LibertarianTreehugger Dec. 28 at 8:11 PM
Biohaven Falls Short in Depression Trial, Could Psychedelics be the Solution? https://jlsfund.substack.com/p/biohaven-falls-short-in-depression $BHVN $MNMD $COMP $ATAI
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 28 at 5:35 AM
🔎 $ATAI Options Scan Update (23:35 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 27 at 5:58 PM
Enter: $ATAI Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.12 - $0.13 Sell Price: $0.23 Profit : +95% (Turn every $1 into $1.95) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
GeorgeJetson17
GeorgeJetson17 Dec. 26 at 9:05 PM
$ATAI Picked up 1,000 more shares!
1 · Reply
BigCatNY
BigCatNY Dec. 26 at 3:09 PM
$ATAI probably will rebound a bit later in the day. You need a strong stomach in 2026.
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 1:03 PM
🔎 $ATAI Options Scan Update (07:03 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 3:20 AM
Enter: $ATAI Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.12 - $0.15 Sell Price: $0.18 Profit : +50% (Turn every $1 into $1.50) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
OmFm
OmFm Dec. 26 at 12:17 AM
$ATAI So if this is a 2-3 year stock then why not go elsewhere.. make some money and then cone back?
3 · Reply
Irichdialed
Irichdialed Dec. 24 at 9:36 PM
$ATAI is it me or does it seem like a great time to get in at this low price, off the highs of early fall. This sector just feels undeniable bullish. I'm still bummed about not selling some a couple months ago but it hasn't been too much of a set back, imo.
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 5:37 PM
Enter: $ATAI Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.10 - $0.11 Sell Price: $0.21 Profit : +111% (Turn every $1 into $2.11) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Latest News on ATAI
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Dec 23, 2025, 7:00 AM EST - 5 days ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Enhanced Fortifies Executive Leadership Team & Board of Directors

Nov 19, 2025, 7:32 PM EST - 5 weeks ago

Enhanced Fortifies Executive Leadership Team & Board of Directors

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

Nov 11, 2025, 9:21 AM EST - 6 weeks ago

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 20, 2025, 5:29 PM EDT - 2 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics

Oct 20, 2025, 9:00 AM EDT - 2 months ago

Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 10:31 PM EDT - 2 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 2 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 16, 2025, 4:10 PM EDT - 2 months ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Oct 13, 2025, 2:21 PM EDT - 2 months ago

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Atai Life Sciences: Still A Decent Prospect - But Only Just

Oct 1, 2025, 2:40 PM EDT - 3 months ago

Atai Life Sciences: Still A Decent Prospect - But Only Just

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Sep 23, 2025, 2:50 PM EDT - 3 months ago

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 23, 2025, 7:00 AM EDT - 3 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Atai Life Sciences N.V. (ATAI) Presents at H.C.

Sep 9, 2025, 6:59 AM EDT - 3 months ago

Atai Life Sciences N.V. (ATAI) Presents at H.C.

atai Life Sciences to Participate in September Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 4 months ago

atai Life Sciences to Participate in September Investor Conferences

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28, 2025, 5:01 PM EDT - 5 months ago

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 10:58 AM EDT - 5 months ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 28, 2025, 8:13 AM EDT - 5 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:16 PM EDT - 5 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 25, 2025, 4:05 PM EDT - 5 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 2, 2025, 2:29 PM EDT - 6 months ago

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 9:28 AM EDT - 6 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:05 AM EDT - 6 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jul 1, 2025, 6:00 AM EDT - 6 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Jun 2, 2025, 6:00 AM EDT - 7 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

atai Life Sciences to Participate in Upcoming Investor Conferences

May 29, 2025, 8:30 AM EDT - 7 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 20, 2025, 7:00 AM EDT - 7 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 14, 2025, 7:00 AM EDT - 8 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

May 13, 2025, 7:01 AM EDT - 8 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Mar 11, 2025, 7:00 AM EDT - 10 months ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 27, 2025, 12:45 PM EST - 10 months ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:10 PM EST - 10 months ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 29, 2025, 11:57 AM EST - 11 months ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Jan 10, 2025, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Psychedelic Stock Deep Dive: Atai Life Sciences

Sep 3, 2024, 2:00 PM EDT - 1 year ago

Psychedelic Stock Deep Dive: Atai Life Sciences

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS CYBN MNMD

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 31, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 24, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Apr 17, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 28, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Mar 27, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Mar 4, 2024, 8:00 AM EST - 1 year ago

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

LibertarianTreehugger
LibertarianTreehugger Dec. 28 at 8:11 PM
Biohaven Falls Short in Depression Trial, Could Psychedelics be the Solution? https://jlsfund.substack.com/p/biohaven-falls-short-in-depression $BHVN $MNMD $COMP $ATAI
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 28 at 5:35 AM
🔎 $ATAI Options Scan Update (23:35 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 27 at 5:58 PM
Enter: $ATAI Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.12 - $0.13 Sell Price: $0.23 Profit : +95% (Turn every $1 into $1.95) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
GeorgeJetson17
GeorgeJetson17 Dec. 26 at 9:05 PM
$ATAI Picked up 1,000 more shares!
1 · Reply
BigCatNY
BigCatNY Dec. 26 at 3:09 PM
$ATAI probably will rebound a bit later in the day. You need a strong stomach in 2026.
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 1:03 PM
🔎 $ATAI Options Scan Update (07:03 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 3:20 AM
Enter: $ATAI Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.12 - $0.15 Sell Price: $0.18 Profit : +50% (Turn every $1 into $1.50) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
OmFm
OmFm Dec. 26 at 12:17 AM
$ATAI So if this is a 2-3 year stock then why not go elsewhere.. make some money and then cone back?
3 · Reply
Irichdialed
Irichdialed Dec. 24 at 9:36 PM
$ATAI is it me or does it seem like a great time to get in at this low price, off the highs of early fall. This sector just feels undeniable bullish. I'm still bummed about not selling some a couple months ago but it hasn't been too much of a set back, imo.
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 5:37 PM
Enter: $ATAI Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.10 - $0.11 Sell Price: $0.21 Profit : +111% (Turn every $1 into $2.11) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
vlentini
vlentini Dec. 24 at 4:13 PM
$ATAI Non vedo come in tanti esaltano questo titolo che prende 1 e perde 4 sistematicamente ,nessuna notizia in attesa con una fusione che è stata deleteria ,al contrario di quanto non si pensasse.
1 · Reply
brodobagginz
brodobagginz Dec. 24 at 3:44 PM
$CMPS $ATAI in the spirit of transparency - i remain bullish but am selling my position in order to be full powder for the new year / reposition accordingly. spent a really long time below break even and been burned too many times by choosing not to sell around my AP - more rational for me to lock in a small profit / be risk-off for a moment. I'll be scaling back in and likely diversifying as I assess the macro picture - happy holidays - see u again in 2026 :)
5 · Reply
Munirb
Munirb Dec. 24 at 2:59 PM
$ATAI
1 · Reply
ClownThePoet
ClownThePoet Dec. 24 at 2:50 PM
$ATAI come to $CMPS
2 · Reply
ReciprocalReturns
ReciprocalReturns Dec. 24 at 12:13 PM
$ATAI The next phase will be defined by how management navigates capital constraints while advancing core initiatives. Failure to demonstrate progress would likely keep valuation capped.
0 · Reply
spra
spra Dec. 24 at 11:27 AM
$ATAI
0 · Reply
spra
spra Dec. 24 at 11:27 AM
$ATAI $MNMD
0 · Reply
spra
spra Dec. 24 at 11:23 AM
$ATAI
0 · Reply
spra
spra Dec. 24 at 11:22 AM
$ATAI $BYND Something fishy sus happening on Stocktwits as well. Subjectively, there is insane amount of chatter on the $BYND page, as well as the bullish tagged ideas seem to outnumber bearish each day. It's however been categorized as "bearish" and 'low volume" for quite long. Meanwhile, another great stock I am invested long in, $ATAI, has nowhere near that level of constant chatter, yet it is considered active/high volume.
1 · Reply
GeorgeJetson17
GeorgeJetson17 Dec. 24 at 6:18 AM
$ATAI https://youtu.be/Hp_QUxUaTo8?si=A9SFhCwdR6cYnMqi
0 · Reply
GeorgeJetson17
GeorgeJetson17 Dec. 24 at 3:43 AM
$ATAI Seeing ATAI to from extremely bearish at the start of the day to 71 bullish is just a reminder that most people on this board focus their bull/bear rating on how the stock does on a given day, which is NOT how you want to invest in biotech. FWIW, I think ATAI could be a fun day trading stock given the massive swings, but for ATAI if you’re not willing to wait 2-3 years for significant gains, it’s probably not the right stock for you (and I say this as someone who’s been holding/adding since 2022).
1 · Reply
wmoller
wmoller Dec. 23 at 11:52 PM
$ATAI I feel like this whole forum is just day traders...everyone is so concerned with the smallest/most insignificant SP moves...the real money...my friends..is still a ways out...like 2-3 years...although I do think we'll be back in double-digits by 2H 2026...the multi-generational wealth money that is...hopefully a few people here have the patience to wait around long enough to grab it.
2 · Reply